TAP1

transporter 1, ATP binding cassette subfamily B member, the group of ATP binding cassette subfamily B

Basic information

Region (hg38): 6:32845209-32853816

Previous symbols: [ "ABCB2" ]

Links

ENSG00000168394NCBI:6890OMIM:170260HGNC:43Uniprot:Q03518AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • MHC class I deficiency (Moderate), mode of inheritance: AR
  • MHC class I deficiency (Supportive), mode of inheritance: AR
  • MHC class I deficiency (Strong), mode of inheritance: AR
  • MHC class I deficiency (Strong), mode of inheritance: AR
  • MHC class I deficiency (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
MHC class I deficiency 1ARAllergy/Immunology/Infectious; PulmonaryIndividuals may manifest with frequent and severe infections (including early-onset severe bacterial infections), and antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; For pulmonary manifestations, treatment recommendations analogous to those in individuals cystic fibrosis have been recommended; Immunosuppressive therapy may be contraindicatedAllergy/Immunology/Infectious; Pulmonary3891604; 10074495; 10074494; 10931128; 17498556; 17982230; 17315195; 18668571
The condition has been reported as possibly related to increased risk of malignancy as well as infectious manifestations

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the TAP1 gene.

  • MHC class I deficiency (15 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the TAP1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
103
clinvar
6
clinvar
112
missense
155
clinvar
9
clinvar
9
clinvar
173
nonsense
10
clinvar
2
clinvar
12
start loss
0
frameshift
4
clinvar
4
inframe indel
3
clinvar
3
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
6
7
13
non coding
1
clinvar
1
clinvar
23
clinvar
47
clinvar
5
clinvar
77
Total 15 2 186 159 20

Highest pathogenic variant AF is 0.0000460

Variants in TAP1

This is a list of pathogenic ClinVar variants found in the TAP1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
6-32845503-T-G Likely benign (Dec 01, 2023)3024794
6-32845587-G-A not specified Uncertain significance (Jun 16, 2023)2573443
6-32845602-C-G MHC class I deficiency Uncertain significance (Sep 12, 2021)1512962
6-32845607-A-G MHC class I deficiency Uncertain significance (Nov 29, 2022)466387
6-32845611-T-C Inborn genetic diseases Uncertain significance (May 11, 2022)2289363
6-32845613-G-A MHC class I deficiency • Inborn genetic diseases Uncertain significance (Mar 25, 2022)2068034
6-32845639-G-A MHC class I deficiency Likely benign (Apr 13, 2023)1133946
6-32845644-G-T MHC class I deficiency Benign (Jan 16, 2024)466386
6-32845659-C-A MHC class I deficiency • Inborn genetic diseases Uncertain significance (Jan 19, 2022)953961
6-32845659-C-G MHC class I deficiency Uncertain significance (Dec 10, 2020)1355919
6-32845671-C-T MHC class I deficiency Uncertain significance (May 20, 2022)936651
6-32845672-G-A MHC class I deficiency Likely benign (Aug 30, 2023)773326
6-32845677-C-A MHC class I deficiency Uncertain significance (Oct 16, 2019)2436953
6-32845681-C-A MHC class I deficiency Likely benign (Aug 17, 2023)2006276
6-32845682-A-C MHC class I deficiency Uncertain significance (Nov 22, 2021)938034
6-32845686-A-G MHC class I deficiency Uncertain significance (Oct 03, 2023)970299
6-32845687-G-T MHC class I deficiency Likely benign (Oct 13, 2023)1141797
6-32845695-G-C MHC class I deficiency Uncertain significance (Oct 13, 2023)569257
6-32845705-C-T MHC class I deficiency Likely benign (Feb 24, 2022)1571268
6-32845721-T-TG MHC class I deficiency Pathogenic (May 21, 2024)3236654
6-32845731-T-C MHC class I deficiency Uncertain significance (Apr 07, 2022)1962218
6-32845732-G-A MHC class I deficiency Likely benign (Oct 22, 2021)1605172
6-32845745-C-T MHC class I deficiency Uncertain significance (Jul 08, 2022)1384330
6-32845746-G-A MHC class I deficiency Uncertain significance (Mar 29, 2022)1516556
6-32845749-A-T MHC class I deficiency Uncertain significance (Sep 07, 2022)1367179

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
TAP1protein_codingprotein_codingENST00000354258 118770
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.000005341.001256990491257480.000195
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.773274300.7600.00002395053
Missense in Polyphen79133.670.591011653
Synonymous1.221681890.8870.00001051794
Loss of Function3.161535.20.4260.00000199358

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0003510.000337
Ashkenazi Jewish0.0001000.0000992
East Asian0.0003830.000381
Finnish0.0002370.000231
European (Non-Finnish)0.0002330.000229
Middle Eastern0.0003830.000381
South Asian0.00006530.0000653
Other0.0003280.000326

dbNSFP

Source: dbNSFP

Function
FUNCTION: Involved in the transport of antigens from the cytoplasm to the endoplasmic reticulum for association with MHC class I molecules. Also acts as a molecular scaffold for the final stage of MHC class I folding, namely the binding of peptide. Nascent MHC class I molecules associate with TAP via tapasin. Inhibited by the covalent attachment of herpes simplex virus ICP47 protein, which blocks the peptide-binding site of TAP. Inhibited by human cytomegalovirus US6 glycoprotein, which binds to the lumenal side of the TAP complex and inhibits peptide translocation by specifically blocking ATP-binding to TAP1 and prevents the conformational rearrangement of TAP induced by peptide binding. Inhibited by human adenovirus E3-19K glycoprotein, which binds the TAP complex and acts as a tapasin inhibitor, preventing MHC class I/TAP association. Expression of TAP1 is down-regulated by human Epstein-Barr virus vIL-10 protein, thereby affecting the transport of peptides into the endoplasmic reticulum and subsequent peptide loading by MHC class I molecules.;
Disease
DISEASE: Bare lymphocyte syndrome 1 (BLS1) [MIM:604571]: A HLA class I deficiency. Contrary to bare lymphocyte syndromes type 2 and type 3, which are characterized by early-onset severe combined immunodeficiency, class I antigen deficiencies are not accompanied by particular pathologic manifestations during the first years of life. Systemic infections have not been described. Chronic bacterial infections, often beginning in the first decade of life, are restricted to the respiratory tract. {ECO:0000269|PubMed:10074494}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Antigen processing and presentation - Homo sapiens (human);Primary immunodeficiency - Homo sapiens (human);Phagosome - Homo sapiens (human);ABC transporters - Homo sapiens (human);Herpes simplex infection - Homo sapiens (human);MECP2 and Associated Rett Syndrome;The human immune response to tuberculosis;Type II interferon signaling (IFNG);antigen processing and presentation;Immune System;Adaptive Immune System;Antigen processing-Cross presentation;Class I MHC mediated antigen processing & presentation;Direct p53 effectors;ER-Phagosome pathway;Antigen Presentation: Folding, assembly and peptide loading of class I MHC (Consensus)

Intolerance Scores

loftool
0.0865
rvis_EVS
2.13
rvis_percentile_EVS
97.95

Haploinsufficiency Scores

pHI
0.0610
hipred
N
hipred_score
0.493
ghis
0.511

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.953

Gene Damage Prediction

AllRecessiveDominant
MendelianHighMediumHigh
Primary ImmunodeficiencyHighHighHigh
CancerHighHighHigh

Mouse Genome Informatics

Gene name
Tap1
Phenotype
mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; neoplasm; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);

Gene ontology

Biological process
adaptive immune response;antigen processing and presentation of peptide antigen via MHC class I;antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent;defense response;protein transport;peptide transport;viral process;antigen processing and presentation of endogenous peptide antigen via MHC class I;cytosol to endoplasmic reticulum transport;vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane
Cellular component
endoplasmic reticulum;endoplasmic reticulum membrane;microtubule organizing center;membrane;integral component of membrane;integral component of endoplasmic reticulum membrane;phagocytic vesicle membrane;endoplasmic reticulum-Golgi intermediate compartment membrane;MHC class I peptide loading complex;TAP complex
Molecular function
protein binding;ATP binding;peptide antigen-transporting ATPase activity;MHC class Ib protein binding;MHC class I protein binding;peptide antigen binding;ATPase activity, coupled to transmembrane movement of substances;protein homodimerization activity;ADP binding;TAP1 binding;TAP2 binding;peptide transmembrane transporter activity